Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Smart Contact Lenses for Blood Glucose Monitoring
Researchers at Yonsei University, along with their counterparts from other leading institutions, announced a significant breakthrough in diabetes management with the development of smart contact lenses. These lenses are capable of analyzing components in tears to monitor blood glucose levels…
UV Radiation at Outdoor Events Linked to Photokeratitis
In a recent publication in JAMA Ophthalmology, researchers have highlighted the potential dangers of ultraviolet (UV) radiation during outdoor recreational activities, particularly pointing to its association with photokeratitis. The study, led by Julia Y.Y. Chan, M.B.B.S., from the Chinese University…
Staar Surgical and IQ Laser Vision Expand EVO ICL Use in the US
Staar Surgical announced a strategic partnership with IQ Laser Vision, a prominent vision correction organization with locations throughout California and Texas. This collaboration aims to significantly increase the use of EVO ICL lenses for surgical vision correction, specifically targeting patients…
AsclepiX Completes Enrollment in DISCOVER Trial for Wet AMD
AsclepiX Therapeutics has successfully completed the enrollment for the DISCOVER trial (NCT05859776), which evaluates the safety and tolerability of three different doses of AXT107 (gersizangitide) in patients with wet Age-related Macular Degeneration (AMD). Trial Design and Objectives The trial includes…
EyePoint’s Duravyu Misses Phase 2 NPDR Trial Goal
EyePoint Pharmaceuticals announced the topline results from its phase 2 PAVIA clinical trial, which evaluated the efficacy of Duravyu (vorolanib intravitreal insert), formerly known as EYP-1901, in treating non-proliferative diabetic retinopathy (NPDR). The trial revealed that Duravyu did not achieve…
Lumibird Launches C.DIAG for Dry Eye Disease
Lumibird Medical has unveiled its latest innovation, the C.DIAG, marking a significant advancement in dry eye diagnostic technology. Integrated with AI algorithms, this new component of the C.SUITE is designed to enable the diagnosis, treatment, and education of dry eye…
Early Patching Shows Promise for Lazy Eye Treatment
A recent study conducted by experts from the University of Leicester sheds light on a potentially more effective treatment approach for children with amblyopia, commonly known as lazy eye. Published in The Lancet, the study challenges the conventional method of…
FDA Accepts Eluminex’s IND for DME Antibody
Eluminex Biosciences announced the acceptance of its EB-105 Investigational New Drug (IND) application by the FDA. This significant milestone marks a pivotal moment in the advancement of medical science, particularly in the realm of Diabetic Macular Edema (DME) treatment. EB-105:…
Emmecell Completes Dosing in Key Corneal Edema Trial
Emmetrope Ophthalmics, a leader in cell-based therapies for severe eye diseases, today announced the completion of the final dose administration in its U.S. clinical trial for EO2002, targeting the treatment of corneal edema. EO2002 Advances Toward Phase 3 This milestone…
Inflammasome Therapeutics Begins GA Clinical Trial
Inflammasome Therapeutics has officially dosed the first patient in a pioneering clinical trial aimed at treating geographic atrophy (GA) resulting from age-related macular degeneration (AMD). This trial, a first-in-class study for a sustained release implant, is sponsored by the University…